Savara Inc Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Savara Inc (SVRA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.29 per share for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-06.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2017-03-06
- Savara Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2013-06-30 was $0.40.
- Savara Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2013-03-31 was $0.53.
- Savara Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2012-09-30 was $0.68, a 76.87% decline year-over-year.
- Savara Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2012-06-30 was $0.00, a 100.00% decline year-over-year.
- Savara Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2016 was $0.29, a 30.95% decline from fiscal 2015.
- Savara Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2015 was $0.42, a 16.00% decline from fiscal 2014.
- Savara Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2014 was $0.50, a 21.95% increase from fiscal 2013.
- Savara Inc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2013 was $0.41, a 32.79% decline from fiscal 2012.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.29 10-K · filed 2017-03-06 | |||
| 2015-12-31 | $0.42 10-K · filed 2017-03-06 | |||
| 2014-12-31 | $0.50 10-K · filed 2017-03-06 | |||
| 2013-12-31 | $0.41 10-K · filed 2015-03-24 | |||
| 2013-06-30 | $0.40 10-Q · filed 2013-08-05 | $0.42 10-Q · filed 2013-08-05 | ||
| 2013-03-31 | $0.53 10-Q · filed 2013-05-15 | |||
| 2012-12-31 | $0.61 10-K · filed 2014-03-26 | |||
| 2012-09-30 | $0.68 10-Q · filed 2012-11-05 | $0.68 10-Q · filed 2012-11-05 | ||
| 2012-06-30 | $0.00 10-Q · filed 2012-08-06 | $0.00 10-Q · filed 2012-08-06 | ||
| 2011-12-31 | $1.52 10-K · filed 2013-03-19 | |||
| 2011-09-30 | $2.94 10-Q · filed 2012-11-05 | $2.63 10-Q · filed 2012-11-05 | ||
| 2011-06-30 | $2.07 10-Q · filed 2012-08-06 | $2.05 10-Q · filed 2012-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |